Cargando…
Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as firs...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448405/ https://www.ncbi.nlm.nih.gov/pubmed/34001702 http://dx.doi.org/10.1097/CAD.0000000000001088 |
_version_ | 1784569235581698048 |
---|---|
author | Liu, Zhiyong Liu, Cuiping Yao, Weitao Gao, Songtao Wang, Jiaqiang Zhang, Peng Ge, Hong |
author_facet | Liu, Zhiyong Liu, Cuiping Yao, Weitao Gao, Songtao Wang, Jiaqiang Zhang, Peng Ge, Hong |
author_sort | Liu, Zhiyong |
collection | PubMed |
description | Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as first-line treatment in patients with metastatic STS between December 2018 and September 2019. A total of 30 patients with metastatic STS were included and followed up retrospectively. One patient had complete response (CR), 10 patients obtained partial response, and 13 patients achieved stable disease. The objective response rate was 36.7% and the disease control rate was 80%. The median progression-free survival (PFS) was 8 months (95% CI: 6.30–10.64). The most frequent any grade adverse events were nausea (66.7%), fatigue (60%), and vomiting (40%). Neutropenia (20%) was the most common grade 3/4 adverse events, followed by leucopenia (13.3%) and febrile neutropenia (6.7%). No death related to treatment was observed during the drugs administration. Toripalimab combined with doxorubicin is effective in patients with metastatic STS as first-line treatment with manageable adverse events. |
format | Online Article Text |
id | pubmed-8448405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-84484052021-09-20 Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study Liu, Zhiyong Liu, Cuiping Yao, Weitao Gao, Songtao Wang, Jiaqiang Zhang, Peng Ge, Hong Anticancer Drugs Preclinical Reports Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as first-line treatment in patients with metastatic STS between December 2018 and September 2019. A total of 30 patients with metastatic STS were included and followed up retrospectively. One patient had complete response (CR), 10 patients obtained partial response, and 13 patients achieved stable disease. The objective response rate was 36.7% and the disease control rate was 80%. The median progression-free survival (PFS) was 8 months (95% CI: 6.30–10.64). The most frequent any grade adverse events were nausea (66.7%), fatigue (60%), and vomiting (40%). Neutropenia (20%) was the most common grade 3/4 adverse events, followed by leucopenia (13.3%) and febrile neutropenia (6.7%). No death related to treatment was observed during the drugs administration. Toripalimab combined with doxorubicin is effective in patients with metastatic STS as first-line treatment with manageable adverse events. Lippincott Williams & Wilkins 2021-05-14 2021-10 /pmc/articles/PMC8448405/ /pubmed/34001702 http://dx.doi.org/10.1097/CAD.0000000000001088 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Preclinical Reports Liu, Zhiyong Liu, Cuiping Yao, Weitao Gao, Songtao Wang, Jiaqiang Zhang, Peng Ge, Hong Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title | Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title_full | Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title_fullStr | Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title_full_unstemmed | Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title_short | Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
title_sort | efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study |
topic | Preclinical Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448405/ https://www.ncbi.nlm.nih.gov/pubmed/34001702 http://dx.doi.org/10.1097/CAD.0000000000001088 |
work_keys_str_mv | AT liuzhiyong efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT liucuiping efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT yaoweitao efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT gaosongtao efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT wangjiaqiang efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT zhangpeng efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy AT gehong efficacyandsafetyoftoripalimabcombinedwithdoxorubicinasfirstlinetreatmentformetastaticsofttissuesarcomasanobservationalstudy |